Camelot | June 06, 2022
After a rigorous agency selection process, Camelot Strategic Marketing & Media has been chosen as media buying and planning agency for healthcare technology company Cue Health (“Cue”) as it aims to pioneer the digital transformation of healthcare, beginning with diagnostics.
The scope of Camelot’s work for Cue includes integrated media planning and buying across Cue’s growing diagnostic platform, aimed at providing better patient outcomes by delivering on the promise of timely, informed, and connected healthcare.
“There is no question that Cue Health is on the leading edge of healthcare technology. We’re thrilled to align our passion for innovation, deep data and analytics, and creative digital media and marketing strategy to help drive their success into the future.”
Sam Bloom, CEO of Camelot Strategic Marketing & Media
Cue empowers people to live their healthiest lives by giving individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue launched the first FDA-authorized COVID-19 molecular test for at-home and over-the-counter use as well as professional point-of-care use. Outside the U.S., Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore’s Health Sciences Authority.
The company is developing future care offerings across several categories, including respiratory health, sexual health, cardiac and metabolic health, women's health, men's health, and chronic disease management.
Within the health and wellness space, Camelot also works with Baylor Scott & White Health, the largest not-for-profit healthcare system in Texas and one of the largest in the U.S., and Glo, a digital health platform and app providing live and on-demand yoga, meditation, Pilates and fitness classes.
Celebrating 40 years in the media and marketing industry, Dallas-based Camelot Strategic Marketing & Media, is a fact-based, bottom-up, independent agency with 150 employees in cities across the U.S. – including Dallas, New York, Los Angeles and Baltimore. We partner with a select group of the world’s biggest brands – from TurboTax to Whole Foods to Michaels – to provide media-agnostic, transparent, insight-driven media and marketing strategy and execution.
Kareo | April 04, 2022
Dr. Daniel Spriggs, a long-time Kareo user at his former practices, chose to continue using the integrated platform for his new practice the Perdido Bay Medical Group because of its functionality, familiarity, and ease of use. Dr. Spriggs was previously part of other medical groups, and so he needed to develop a new online identity when he opened his new practice. In the first 60 days following implementation, PatientPop’s solution improved the practice’s visibility online garnering over 1,500 new website visitors. Simultaneously, PatientPop helped solidify 70 new patient reviews with an average of 5 out of 5-star ratings. Improving the practice website’s SEO brought in over 500 organic website connections.
“Kareo’s platform has allowed me to create workflows that mimic how I work, making it easier for me to deliver care to my patients. It was still the best choice when it came to a solution for my new practice. Even though I haven’t used PatientPop for very long, it has already improved my website performance greatly by making my brand presence more cohesive and is helping to bring in new patients. It's a tremendous benefit that Kareo and PatientPop have merged because I don’t have to rely on disparate systems which are often confusing, not as fiscal, and don’t deliver the best results.”
Kareo and PatientPop announced theymerged in 2021to form Tebra. The combined company’s mission is to equip independent practices with digital tools to deliver modernized care. The all-in-one solution can help providers support and attract new patients, get paid quickly, and operate more efficiently.
“Tebra’s all-in-one platform is unlocking better healthcare for small practices to modernize care delivery and improve the patient experience,” Andrea Kowalski, Senior Vice-President of Product for Kareo, said. “Our partnership with the Perdido Bay Medical Group illustrates our ability to tailor solutions to what is most important to our client’s needs. We will continue to enhance and simplify our solutions to drive practice transformation.”
About the Perdido Bay Medical Group
The Perdido Bay Medical Group is a family medicine practice serving adults of all ages and children as young as four years old in Lillian, Alabama. Experienced family medicine physician Daniel Spriggs, MD, launched the practice in 2021 when he discovered that the Lillian community needed more than the ordinary family medicine practices. The Perdido Bay Medical Group offers chronic disease management, acute illness care, arthritis care, geriatrics, and specialized care for disability and special-needs patients.
PatientPopis an industry leader in practice growth technology with a platform that helps thousands of providers promote their practice, attract and acquire patients, and retain them, for a thriving business. The integrated platform eases and enhances the patient journey from start to finish, with a streamlined digital workflow that significantly reduces work for providers and staff. PatientPop has been recognized with many industry awards and accolades, including the Inc. 500, Deloitte Fast 500, Entrepreneur 360, Consumer World Awards, Capterra Shortlist, G2 Leader, and Silicon Review 50 Fastest Growing Companies. PatientPop has headquarters in Santa Monica, California.
Kareois a cloud-based healthcare technology platform built to meet the unique needs of independent practices in dozens of specialties. Today, Kareo helps over 80,000 providers in 50 states deliver outstanding patient care and run more efficient and profitable practices. The Kareo technology platform helps providers find more patients, manage patient care with a fully certified and easy-to-use EHR, and get paid quickly within a unified, easy-to-use solution. Kareo has received extensive industry recognition, including the2021 Best in KLAS award for Small Practice Ambulatory EMR/PM Solutions, the Deloitte Technology Fast 500, Inc. 5000, and a ranking at the top of Gartner’s Leader Quadrant in the FrontRunners Software Analysis of EHR. Kareo’s headquarters are based in Irvine, California.
Adaptiiv Medical Technologies Inc. | May 09, 2022
Adaptiiv Medical Technologies Inc. is collaborating with HP Inc. and Varian, a Siemens Healthineers company to advance the quality of and access to personalized cancer care for U.S. patients with 3D printed medical devices.
HP's Multi Jet Fusion platform provides access to leading 3D printing technology that is used to produce high-quality, flexible, patient-specific parts at high throughput. HP 3D printing is suitable for use in healthcare because of the speed, quality, and economic advantages gained through HP's scalable manufacturing processes.
"The combined technology scale of HP and Varian, along with the leading-edge personalization workflow of Adaptiiv, provides the improved solution that clinicians and patients deserve," said Louis Kim, Vice President, 3D Printing at HP. HP is proud to be a part of this collaboration to help advance the treatment of cancers worldwide."
Adaptiiv will also work with Varian to expand access to personalized, patient-specific 3D printed medical devices. For more than 70 years, Varian has developed, built, and delivered innovative cancer care technologies and solutions for clinical partners around the globe to help them treat millions of patients each year. This agreement advances Varian's commitment to meeting evolving customer needs and improving the patient experience.
"We are energized by Adaptiiv's innovation and this opportunity with HP to further expand our cancer care ecosystem. Addressing our customers' needs is our top priority, and we are confident that this commercial commitment will help us do just that by advancing interoperability with Adaptiiv's 3D printed medical devices for external beam radiation therapy,"
Ben Moga, Director, Strategic Alliances and Synergy Investments at Varian
Earlier this year, Adaptiiv received U.S. FDA 510(k) clearance for the Adaptiiv On Demand service to manufacture and deliver 3D printed patient-specific medical devices. 3D printed medical devices conform to patient anatomy thereby improving the accuracy of dose delivery while the integration of Adaptiiv software into clinical workflows provides improved efficiencies, such as reducing patient set up time both in CT simulation and on the treatment unit.
"This is a tremendous milestone for Adaptiiv's vision to democratize personalization in radiation treatment," said Adaptiiv CEO, Alex Dunphy. "Collaborating with brands like HP and Varian who stand for quality and innovation will ensure our solutions reach patients around the world. The last mile of radiation therapy needs to evolve and our solutions provide greater access to personalized care, while improving treatment and creating workflow efficiencies for cancer centres around the world."
Adaptiiv Medical Technologies Inc. has a software platform that works in conjunction with 3D printing to create medical devices for use in radiation oncology. Adaptiiv is shaping the future of personalized healthcare through innovation and collaboration with industry leaders throughout the world.
FUTURE OF HEALTHCARE
BD (Becton, Dickinson and Company) | April 23, 2022
BD a leading global medical technology company, announced the formation of the Sustainable Medical Technology Institute, a model of practice within the organization that will bring together BD researchers and engineers, as well as quality, regulatory, policy and operational expertise, to focus on reducing the environmental impact of the company's product portfolio in three areas, including adopting sustainable product design strategies, developing and deploying sustainable sterilization technologies, and addressing materials of concern.
The Institute will serve as an example of how the company continues to advance the world of health by prioritizing high-quality, safe products for patients, while furthering its environmental, social and governance strategy.
"As part of our ESG strategy, we made commitments in specific areas where we see the most opportunity for BD to create meaningful, measurable change over the next decade. In order to achieve these commitments, we established a set of goals to track and measure our success, and this includes how to reduce the environmental impact of our product portfolio and address our customers' sustainability needs. These priorities led us to form the Sustainable Medical Technology Institute."
Maureen Mazurek, vice president, sustainability and environmental health and safety at BD
Dr. Amit Limaye, director of the Sustainable Medical Technology Institute and director of sustainability research and development at BD, added, "By empowering our teams to tap into deep expertise in areas like engineering and materials science, coupled with access to breakthrough research, technologies, and government and academic partnerships, we are well-positioned to be the best environmental stewards of our portfolio. It is our vision to create a strategic roadmap that will be integral across the organization, demonstrating how an ethical and sustainable company can drive growth, while meeting patient and customer needs in the most environmentally sustainable way possible."
The Institute will operate in North America, Europe and Asia, and will collaborate with cross-functional teams within the company's business units, inclusive of research and development, regulatory, quality, policy and operations roles, with the goal of ensuring accountability and a streamlined approach to sustainability efforts, as well as further address sustainability needs within the industry and global regulatory bodies. Key initial efforts include reestablishing a set of minimum environmental and human health criteria for new products and product changes aligned with the company's 2030+ ESG commitments and goals, and identifying new ways to reduce, reuse, recycle or replace materials. These efforts will inform the company's product life cycle roadmap and enable adoption of a sustainable-by-design product development process.
is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.